Efficacy of Plant-Made Human Recombinant ACE2 against COVID-19 in a Golden Syrian Hamster Model
Authors:
- Choon-Mee KimCKChoon-Mee Kim
- Dong-Min KimDKDong-Min Kim
- Mi-Seon BangMBMi-Seon Bang
- Jun-Won SeoJSJun-Won Seo
- Da-Young KimDKDa-Young Kim
- Na-Ra YunNYNa-Ra Yun
- Sung-Chul LimSung-Chul Lim
- Ju-Hyung LeeJLJu-Hyung Lee
- Eun-Ju SohnESEun-Ju Sohn
- Hyangju KangHKHyangju Kang
- Kyungmin MinKMKyungmin Min
- Bo-Hwa ChoiBCBo-Hwa Choi
Open Access
Abstract
Coronavirus disease 2019 (COVID-19) is a novel infectious respiratory disease caused by SARS-CoV-2. We evaluated the efficacy of a plant-based human recombinant angiotensin-converting enzyme 2 (hrACE2) and hrACE2-foldon (hrACE2-Fd) protein against COVID-19. In addition, we analyzed the antiviral activity of hrACE2 and hrACE2-Fd against SARS-CoV-2 using real-time reverse-transcription PCR and plaque assays. The therapeutic efficacy was detected using the Golden Syrian hamster model infected with SARS-CoV-2. Both hrACE2 and hrACE2-Fd inhibited SARS-CoV-2 by 50% at concentrations below the maximum plasma concentration, with EC50 of 5.8 μg/mL and 6.2 μg/mL, respectively. The hrACE2 and hrACE2-Fd injection groups showed a tendency for decreased viral titers in nasal turbinate tissues on day 3 after virus inoculation; however, this decrease was not detectable in lung tissues. Histopathological examination on day 9 after virus inoculation showed continued inflammation in the SARS-CoV-2 infection group, whereas decreased inflammation was observed in both the hrACE2 and hrACE2-Fd injection groups. No significant changes were observed at other time points. In conclusion, the potential therapeutic efficacy of plant-based proteins, hrACE2 and hrACE2-Fd, against COVID-19 was confirmed in a SARS-CoV-2-inoculated Golden Syrian hamster model. Further preclinical studies on primates and humans are necessary to obtain additional evidence and determine the effectiveness of these therapies.Keywords
Funding Information
- Chosun University
This publication has 29 references indexed in Scilit:
- Pharmacokinetics and Pharmacodynamics of Recombinant Human Angiotensin-Converting Enzyme 2 in Healthy Human SubjectsClinical Pharmacokinetics, 2013
- A Carboxy-Terminal Trimerization Domain Stabilizes Conformational Epitopes on the Stalk Domain of Soluble Recombinant Hemagglutinin SubstratesPLOS ONE, 2012
- ACE2, a promising therapeutic target for pulmonary hypertensionCurrent Opinion in Pharmacology, 2011
- Angiotensin II–Mediated Microvascular ThrombosisHypertension, 2010
- Mann‐Whitney U test and Kruskal‐Wallis test should be used for comparisons of differences in medians, not means: Comment on the article by van der Helm‐van Mil et alArthritis & Rheumatism, 2009
- A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injuryNature Medicine, 2005
- Angiotensin-converting enzyme 2 protects from severe acute lung failureNature, 2005
- Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entryProceedings of the National Academy of Sciences, 2005
- Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor associationProceedings of the National Academy of Sciences, 2004
- Angiotensin II Induces Interleukin-6 Transcription in Vascular Smooth Muscle Cells Through Pleiotropic Activation of Nuclear Factor-κB Transcription FactorsCirculation Research, 1999